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We recently showed that Magic-F1 (Met-activating genetically improved chimeric factor 1), a human recombinant protein derived
from hepatocyte growth factor/scatter factor (HGF/SF) induces muscle cell hypertrophy but not progenitor cell proliferation, both
in vitro and in vivo. Here, we examined the temporal and spatial expression pattern of Magic-F1 in comparison with Pax3 (paired
box gene 3) transcription factor during embryogenesis. Ranging from 9.5 to 17.5 dpc (days post coitum) mouse embryos were
analyzed by in situ hybridization using whole mounts during early stages of development (9.5–10.5–11.5 dpc) and cryostat sections
for later stages (11.5–13.5–15.5–17.5 dpc). We found that Magic-F1 is expressed in developing organs and tissues of mesenchymal
origin, where Pax3 signal appears to be downregulated respect to the wt embryos. These data suggest that Magic-F1 could be
responsible of muscular hypertrophy, cooperating with Pax3 signal pathway in skeletal muscle precursor cells.
1. Introduction
Muscular hypertrophy is controlled by both muscle growth
and muscle atrophy. These apparently contrasting biological
processes share key molecules triggering active transcrip-
tional programs to induce skeletal muscles atrophy or hyper-
trophy.
The IGF-1 (insulin-like growth factor-1) pathway aﬀects
both hypertrophy and atrophy, increasing protein synthesis
and inhibiting the expression of transcription factor FOXO
(forkhead box O), respectively. A key molecular player
downstream of IGF-1 receptor is Akt (Abelson leukemia
kinase) that when phosphorylated activates protein synthesis
via mTOR (mammalian target of rapamycin). The two
main actors to negatively control the muscle growth are
myostatin and atrogin-1. Myostatin belongs to the TGF-β
(transforming growth factor beta) family, and it is expressed
and secreted predominantly in skeletal muscle, functioning
as negative regulator of muscle growth. Mice, sheep, cattle,
and humans that present mutations in myostatin gene show
a double-muscling phenotype, characterized by extensive
muscular hypertrophy [1–4]. In vitro myostatin is able to
positively aﬀect the expression of ubiquitin ligases, involved
in muscle atrophy [5]. Interestingly, myostatin treatment
blocks the IGF1-AKT pathway, allowing the increased
expression of atrogin-1, directly involved in muscle atrophy
[6]. Among themuscle growth regulators, hepatocyte growth
factor (HGF/SF) [7–9], initially unveiled as the major
inducers of hepatogenesis, is involved in muscle stem-cell
activation through its tyrosine kinase receptor Met [10–14],
containing a Pax3-binding site. Pax3 is an early transcription
factor involved in embryonic and adult myogenesis, and it is
expressed in the lateral dermomyotome of all somites, where
also is present Met [15]. Transgenic animals generated to
interfere in HGF-Met signaling show abnormality in several
muscles during embryogenesis [16–18]. Moreover, HGF-Met
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pathway is important in muscle regeneration, since, sustains
the proliferation of muscle stem cells after their activation
[19–22]. However, HGF expression is downregulated during
myogenesis in order to allow the satellite cells to exit the cell
cycle, avoiding a delay in the regeneration process [23, 24].
The production of recombinant proteins allows the
great advantage to select a specific biological eﬀect of a
given protein able to trigger diﬀerent biological processes.
We recently generated transgenic mice expressing an HGF-
related recombinant protein, named Magic factor-1 (Met-
activating genetically improved chimeric factor-1 or Magic-
F1) and expressed exclusively in skeletal muscles [25].
This animal model develops muscular hypertrophy with no
evident side eﬀects or hyperplasia. However, the expression
pattern of the transgene in early embryogenesis is unknown.
The eﬀect of Magic-F1 recombinant protein in skeletal
muscle tissue oﬀers biological advantages over HGF. Magic-
F1 is able to promote myocytes survival and enhance
muscle regeneration and a lack of any mitogenic activity
could allow a potential safe use of the recombinant protein
as therapeutic cytokine for muscle degenerative disorders,
promoting muscle regeneration without the potential risk
of stimulating uncontrolled proliferation. Because of its
selective stimulation of hypertrophy, Magic-F1 is a novel
molecule with potential applicative perspective to counteract
muscle wasting in muscle diseases such as cachexia or
muscular dystrophy.
Here, we evaluate the localization of transgene Magic-
F1 in comparison with Pax3, the earliest myogenic tran-
scription factor, in early and late embryogenesis using
in situ hybridization on whole-mount and cryosections of
transgenic and wt mouse embryos.
2. Materials and Methods
2.1. Mouse Embryos and Staging. Embryos for in situ hy-
bridization were dissected from CD1 wt (wild-type) female
mice mated with homozygous Magic-F1 transgenic male
mice (Stem Cell Research Institute, H. S. Raﬀaele, Milan,
Italy). Embryos were generated using timed mating, with the
morning vaginal plug designated as E0.5.
2.2. Genotyping of Magic-F1 Embryos. Magic-F1 is a recom-
binant protein containing two HGF NK2 domains joint
by a linker. The exact amino acidic sequence of Magic-F1
corresponds to residues 1–285 of human HGF (Gene Bank
no.M73239), a linker with the sequence (GGGGS)3; residues
30–285 of human HGF, and a poly-histidine tag with the
sequence DDDKHHHHHH. We generated transgenic mice
expressing Magic-F1 construct into a plasmid containing the
1.500-bp (base pair) fragment of the MLC (myosin light
chain) promoter, an 840-bp fragment of SV40 poly(A), and
a 900-bp fragment from the 3′ end of the MLC1f/3f gene,
which acts as an enhancer as previously reported [25].
To determinate the genotypes of the embryos used in
this study, the yolk sack was removed from each embryo
and was used to prepare genomic DNA (deoxyribonucle-
ic acid), according to a modified protocol using pro-
teinase K digestion, isopropanol extraction, and ethanol
precipitation. Oligonucleotide primers FW (forward) (5′-
GTGTCAAGGTTCTATTAGGCACTA-3′) and REV (reverse)
(5′-GTCCTTTACCAATGATGCAGTTTC-3′), were used to
amplify a 331 bp fragment specific to Magic-F1. For each
sample, 20 ng of genomic DNA was subjected to a cycle of
predenaturation (94◦C, 3 minutes and 30 seconds), then to
30 cycles of amplification consisting of denaturing (94◦C,
15 seconds), annealing 56◦C, 30 seconds) and extension
(72◦C, 45 seconds), followed by two additional extensions
at 72◦C, 7 minutes). The amplified products were analyzed
by agarose gel electrophoresis in TBE (Tris Borate EDTA)
1X. To confirm that the absence of the band of some
samples was due to the absence of Magic-F1 gene and not
to the absence of DNA, a PCR (polymerase chain reac-
tion) has been performed for GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) gene, using oligonucleotide
primers FW (5′-GGGTGGAGCCAAACGGGT-3′) and REV
(5′-GGAGTTGCTGTTGAAGTCGCA). For each sample,
20 ng of genomic DNA was subjected to a cycle of predenat-
uration (94◦C, 5 minutes), then to 35 cycles of amplification
consisting of denaturing (94◦C, 60 seconds), annealing
(60◦C, 60 seconds) and extension (72◦C, 60 seconds), fol-
lowed by an additional extension at 72◦C, 7 minutes.
2.3. Plasmid and Riboprobe Synthesis. As probes for
hybridization experiments, human Magic-F1 cDNA
(complementary deoxyribonucleic acid) (1759 bp) was
amplified using oligonucleotide primers FW (5′-
ATGTGGGTGACCAACTCCTG-3′) and REV (5′-
CTAGTGGTGGTGGTGGTGGTG-3′). The amplified pro-
ducts were analyzed by agarose gel electrophoresis in TBE
1X. Magic-F1 bands were excised from the gel, and the
Magic-F1 DNA was extracted (QIAquick Gel Extraction
Kit, QIAgen). Magic-F1 fragments were subcloned into the
pGEM-T Easy Vector System (Promega). Nonradioactive
antisense and sense riboprobes were synthesized by in
vitro transcription using digoxigenin-UTP following the
manufactures instructions (Boehringer Mannheim). Magic-
F1 antisense and sense probes were synthesized using SP6/
T7 RNA (ribonucleic acid) polymerase linearization at a
suitable site: pGEM-T carrying Magic-F1 was digested with
BstXI and Magic-F1 antisense probes were synthesized
using T7 RNA polymerase; Magic-F1 sense probes were
synthesized using SP6 RNA polymerase after digestion with
ApaI restriction enzyme. The Pax3 antisense and sense
probes were produced by T7 and SP6 RNA polymerase
from pCMV-sport6.1 (Invitrogen) carrying Pax3 cDNA after
proper linearization with EcoRI and BamH1, respectively.
2.4. In Situ Hybridization. Whole-mount in situ hybridiza-
tion on mouse embryos was performed as described [26].
Briefly, embryos were dissected free of all membranes
in phosphate-buﬀered saline (PBS) and fixed in 4%
paraformaldehyde in PBS for 1-2 h at RT (Room Tem-
perature) with slow rocking speed. After washing twice in
PTW (PBS, 0.1% Tween-20), embryos were washed with
50% MeOH/PTW and 100% MeOH then stored in 100%
MeOH at −20◦C for less than a month. For hybridization,
Journal of Biomedicine and Biotechnology 3
BAM HI
MLC1F
5
Hind III
Linker
(GGGGG)3
XBA I
Poly A Enhancer
3HGF-K2HGF-K2
SAL I
(a)
M + − 1 2 3 4 5 6 7
Magic-F1
331 bp
GAPDH
890 bp
(b)
Figure 1: Magic-F1 transgenic mice. (a) Schematic representation of transgene. (b) Genotyping of 13.5 dpc mouse embryos derived by
hemizygous-matched mice; +, − positive and negative control, respectively.
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Figure 2: Expression of Magic-F1 in whole mount embryos. Lateral view of whole-mount in situ hybridization with digoxigenin labeled
antisense Magic-F1 (a, b, d, e, f, g, h, and i) and sense Magic-F1 (c) cRNA probes as negative control (ctr-). Specific hybrids are visualized as
a purple precipitate in all panels except in (a), 9.5 dpc and (b) 10.5 dpc. (e) Specific Magic-F1 transcripts are detected (f) in the mesodermal
cells of the jaw and hyoid bone; in f, tv: telencephalic vesicles, cmt: mesenchymal cephalic tissue, hb: hindbrain, and ba: branchial arches
where muscles are localized as well as around the eyes; a faint expression is also revealed in tail (g) and dorsal (h) somites, while a strong
signal was selected in somites of fore (f
′
) and hind (h
′
) limb buds (i). In embryos hybridized with sense probe (c) background staining has
not been detected as well as on 11.5 dpc wild type embryo (wt) hybridized with antisense probes (d).
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Figure 3: Transcription expression profile of Pax3 (a–c) and Magic-F1 (d–f) on 11.5 dpc mouse embryos of hemizygous Magic-F1 (a–f)
and wt (g, h) mice by in situ hybridization. In the sagittal section of transgenic embryo, Pax3 riboprobes reveal a strong signal at the level
of hindbrain (arrowhead in a), neuroepithelium of neural tube (arrow in b), and dorsal somites (c); sagittal section of 11.5 dpc embryo
hybridized by Magic-F1 riboprobes (d) shows a similar pattern of Pax3 although no expression was detected at the level of neuroepithelium
of neural tube (arrow in e); specific transcripts are observed in the cervical dorsal (posterior) root ganglion (arrows in c and f) and somites
(arrowheads in f). In 11.5 dpc wt embryo hybridized with Pax3 riboprobes (g), specific transcripts are detected mostly in the cerebellar
primordium (cerebellar rudiment derived from dorsal part of the alar lamina of the Metencephalon) (arrow) and somites in lumbar
region (arrowhead in g), whereas no signal for Magic-F1 has been detected (h). Immunofluorescence analysis confirmed the presence of
recombinant protein at the level of thoracic (i) and lumbar (j) somites in the transgenic embryos, whereas the signal was faint in the wt
embryos (k), probably referred only to the HGF expression at this stage.
embryos were incubated horizontally at 65◦C overnight in
hybridization mix (50% deionized formamide, 1.3xSSC pH
5, 5mM EDTA pH 8, 50 μg/mL Yeast RNA, 0.2% Tween-
20, 0.5%CHAPS, 100 μg/mLHeparin, ddH2O) with 1 μg/mL
digoxigenin-labeled RNA probes. After in situ hybridization,
the embryos were washed in MABT buﬀer (100mM maleic
acid (Sigma), 150mM NaCl, 0.1% Tween-20, pH 7.5) and
NTMT buﬀer (100mM NaCl, 100mM Tris-HCl pH 9.5,
50mM MgCl2, 0.1% Tween-20) and incubate with staining
solution (4.5 μg/m NBT and 3.5 μg/mg BCIP). When the
developed color reached the desired extent, embryos were
washed twice with PTW and refixed in 4% HCHO/0.1%
glutaraldehyde/PTW for 2 h at RT or 4◦C overnight.
In situ hybridization on mouse cryostat sections was
performed according to Sally Dunwoodie, NIMR. Briefly, the
sections were fixed 4% paraformaldehyde in PBS, digested
with proteinase K and postfixed. Sections were prehybridized
in hybridization solution without probe (50% deionized
formamide, 10x salt, 250 μg/mL Yeast RNA, 5x Denhardt’s,
50 μg/mL Heparin, 0.1% Tween, ddH2O) in a humid envi-
ronment at 67◦C for 2 h. After incubation, the prehybridiza-
tion buﬀer was removed and replaced with hybridization
buﬀer containing everything in the prehybridization buﬀer
plus 0.1–1 μg/mL labeled cRNA (complementary ribonucleic
acid) riboprobe, denatured for 5min at 80◦C. A coverslip
was placed over the hybridized area and the slides were
then placed in a moist, closed plastic box and hybridized
overnight at 67◦C h. Following hybridization, the coverslips
were washed oﬀ by dipping into 50% formamide, 1xSSC
prewarmed to 67◦C. The tissue was subjected to stringent
washing at 67◦C in 50% formamide, 1xSSC twice for 30min,
followed by two washes in MABT 1X at RT, for 30min
each. Slides were exposed to BMpurple (Roche) for 2 h.
Slides were fixed in PFA 4% and washed in PBS, three
times for 5min. Hybridization signals were observed and
photographed using a Nikon microscope. As a negative
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Figure 4: Expression of Pax3 andMagic-F1 in 13.5 dpcmouse embryos. (a) Sagittal section of 13.5 dpcmouse hybridized by Pax3 riboprobes.
A weak signal of Pax3 transcripts have been detected in Magic-F1 transgenic embryos (+/−) at the level of somites in thoracic (b) and
lumbosacral region; in the wild-type age-matched embryo (wt) the signal appeared slightly stronger (c). A faint signal was detected at the
same stage in transgenic embryos hybridized by Magic-F1 antisense riboprobes (d); mainly, the transgenic expression was localized at the
level of somites as shown at higher magnification in (e). No signal was detected in wild type embryos (wt) by Magic-F1 antisense riboprobes
(f). Arrowheads show somites.
control, specimens were incubated with hybridization buﬀer
containing digoxigenin labeled riboprobes corresponding to
the sense sequence of Magic-F1.
2.5. Immunochemistry. Cryosections placed in a humid,
closed plastic box were fixed for 10min in 4% paraformalde-
hyde in PBS, permeabilized in 0.2% Triton and incubated,
first, with a blocking buﬀer (2% donkey serum) contain-
ing 1% blocking solution in PBS for 30min at RT and,
then, a second blocking buﬀer (0.5% mouse serum, 0.5%
goat serum) containing 1% Blocking Solution (Candor-
bioscience GmbH) in PBS for 30min at RT, followed
by incubation with primary antibodies (goat polyclonal
antibody anti-HGF, 1 : 100 and Mouse monoclonal antibody
anti-Pax3) diluted in 2% BSA (bovine serum albumine) in
PBS overnight at 4◦C. Sections were rinsed three times in PBS
followed by a 2 h incubation with fluorescein-conjugated
anti-mouse and anti-goat antibodies diluted 1/1500. Slides
were stained with Hoechst dye and mounted in Fluor-
Save. Stained cryosections were observed on an upright
microscope Nikon Vico TE-2000 (Nikon, Japan).
3. Results and Discussion
3.1. PCR Analysis. PCR analysis of Magic-F1 showed trans-
gene expression in all the embryonic developmental stages
analyzed and an example at stage 13.5 dpc is reported in
Figure 1(b). As expected, no signal was detected in the wild-
type embryos due to the high specificity of the primers able
to discriminate between HGF and the recombinant protein
Magic-F1.
3.2. Whole-Mount In Situ Hybridization. Whole-mount in
situ hybridization was performed to detect Magic-F1 and
Pax3mRNA (messenger ribonucleic acid) in embryos at early
stages of development (9.5, 10.5 and 11.5 dpc).
Magic-F1 expression was detected in bone cartilage pri-
mordia, dorsal somites, in tail and limb buds, where Pax3
signal appears to be downregulated respect to the wt
embryos. At 9.5 dpc (30 somite stage) and 10.5 dpc (40
somite stage) (Figures 2(a) and 2(b)), in situ hybridization
analysis with digoxigenin- (DIG-) labeled antisense probes
showed no expression of Magic-F1 transcript. Magic-F1
transcripts (Figure 2(e)) have been detected from stage of
11.5 dpc (58 somite stage) in developing organs and tissues
of mesenchymal origin. Specifically, positive signal was
observed in mesodermal cells of the jaw, hyoid bone and in
pharyngeal (or brachial) arches from which branchiomeric
muscles are formed. This expression profile confirmed the
muscle specificity of the MLC1F (myosin light chain type 1F)
promoter, regulating Magic-F1 transcription. Furthermore,
specific hybrids were also detected around the eyes at the level
of the choroid coat and the sclera, both of mesenchymal ori-
gin, on the ventral and dorsal side of limb buds (Figure 2(d)),
in the dorsal side of some rostral somites (Figure 2(h)), and
in the tail bud (Figure 2(g)). No signal was observed in the
embryos hybridized with the sense riboprobe (Figure 2(i)).
The somites begin to form at the 7.75–8.0 dpc, and, after
condensation, they begin to diﬀerentiate into three compart-
ments: the sclerotome, the dermatome, and myotome. At
11.5 dpc (58 somite stage), Magic-F1 transcripts have been
detected in all three compartments (sclerotome, dermatome,
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Figure 5: Expression of Pax3 and Magic-F1 at 15.5 dpc. Sagittal section of 15.5 dpc mouse hybridized with digoxigenin-labeled antisense
Pax3 riboprobes (a); specific Pax3 transcripts are localized in cartilage primordium of tail vertebral body, cutaneous muscles (arrow) of
thorax and trunk regions and in mid-cervical region of spinal cord (double arrow) as shown in (b); expression was also localized in cartilage
primordium (arrowhead) of dorsal part of shaft region (c); (d) sagittal section of 15.5 dpcmouse hybridized with Magic-F1 cRNA probes and
signal is observed in cartilage primordium of anterior arch of cervical vertebra (arrowheads) and right lobe of thymus gland (arrow); specific
Magic-F1 transcripts are also localized in cutaneous muscles (arrow) of thorax and trunk regions (e); (f) higher magnification cartilage
primordium of dorsal part of shaft region of ribs.
and myotome) originating from somites. No signal was
detected in wt embryos at the same stage.
3.3. In Situ Hybridization on Cryostat Sections. In situ hy-
bridization on 10 μm-cryostat sections was performed to
localize Magic-F1 and Pax3 transcripts in embryos at later
stages of development (11.5–13.5–15.5–17.5 dpc), since the
large size of the samples did not allow a full penetration of
the probes.
At 11.5 dpc, transgenic mouse embryos showed Pax3
transcripts expression at the level of hindbrain (Figure 3(a)),
neuroepithelium of neural tube (Figure 3(b)), and dorsal
somites (Figure 3(c)). Magic-F1 riboprobes showed a similar
expression pattern (Figure 3(d)) reported for Pax3 although
the signal was no detected at the level of neuroepithelium
of neural tube in embryos at the same stage (Figure 3(e)).
Specific transcripts were also observed in the cervical dorsal
(posterior) root ganglion (Figures 3(c) and 3(f)) and somites
(Figure 3(f)). In addition, at this stage, Pax3 signal can be
observed in wt embryos mainly in the cerebellar primordium
and somites in lumbar region (Figure 3(f)), whereas no
signal for Magic-F1 has been detected (Figure 3(g)).
3.4. Localization of Pax3 and Magi-F1 Proteins and Tran-
scripts. Immunofluorescence analysis was performed to
localize the presence of recombinant protein. In transgenic
embryos at 11.5 dpc, MAGIC-F1 was mainly detected at
the level of thoracic (Figure 3(i)) and lumbar (Figure 3(j))
somites, whereas a faint signal was detected in wt embryos
(Figure 3(k)), probably due to the interference with HGF
localization in the same area. At 13.5 dpc, transgenic embryos
showed a weak signal of Pax3 at the level of somites in
thoracic (Figure 4(a)) and lumbosacral region (Figure 4(b)),
whereas in the wild-type embryo, the signal appeared slightly
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Figure 6: Expression of Pax3 and Magic-F1 at 17.5 dpc. Specific Pax3 transcripts are localized on sagittal sections of 17.5 dpc at the level of
the head (a), in the nucleus pulposus (b) of lumbar intervertebral disc (arrows) of the trunk, and in cartilage primordium (arrowheads) and
wall of spinal cord in midlumbar region (double arrow) as shown in (b) and in cartilage primordium of dorsal part of ribs (c). (d) Magic-F1
signal was observed at the level of cartilage primordium (arrows) of vertebrae.
stronger (Figure 4(c)). A weak signal have been detected in
transgenic embryos hybridized by Magic-F1 antisense ribo-
probes (Figure 4(d)), where Magic-F1 was mainly expressed
at the level of somites (Figure 4(e)), whereas no signal
was detected in wild-type embryos (Figure 4(f)). Specific
Pax3 transcripts can be detected at later stage (15.5 dpc)
(Figure 5(a)) in cartilage primordium of tail vertebral body,
cutaneous muscles of thorax and trunk regions, and in mid-
cervical region of spinal cord (Figure 5(b)). In addition,
at this stage, Pax3 expression demarcated also cartilage
primordium of dorsal part of shaft region (Figure 5(c)). In
sagittal section of 15.5 dpc embryo hybridized with Magic-
F1 cRNA probes a strong signal was detected in cartilage pri-
mordium of anterior arch of cervical vertebra and right lobe
of thymus gland (Figure 5(d)). Consisted with this, Magic-F1
resulted to be also expressed in cutaneous muscles of thorax
and trunk regions (Figure 5(e)) and in primordium of dorsal
part of shaft region of ribs (Figure 5(f)). From 17.5 dpc
sagittal sections at the level of the head (Figure 6(a)), Pax3
signal was detected in the trunk nucleus pulposus in central
part of lumbar intervertebral disc (Figure 6(b)) and in
cartilage primordium of dorsal part of ribs (Figure 6(c)).
At this stage, Magic-F1 expression was observed at the level
of cartilage primordium of vertebrae (Figure 6(d)). These
data suggest a role of this factor in muscle development
possibly triggering the premature downregulation of Pax3
signal pathway in skeletal muscle precursor cells.
4. Conclusion
Taken together, our data show that Magic-F1 is localized
in specific expression pattern in the developing muscular
tissues. This could be relevant with the muscle phenotype
previously observed in the transgenic animal model. The
recombinant protein can be considered as a novel member
of Met signaling, since it has been shown to interact with,
and thus interfering with, cell migration andmyogenesis. It is
noteworthy that Magic-F1 expression pattern is overlapping
with Pax3, however, limited only in developing muscular
tissue, where exerts its myogenic potential. In fact, Pax3 is
able to activate Myf5 (Myogenic factor 5) myogenic master
gene [25], leading to the formation of skeletal muscle. In
addition, Pax3 orchestrates FGF (fibroblast growth factor)
cascade [27], targeting directly Fgfr4 (fibroblast growth fac-
tor receptor 4) and Sprouty1 known to inhibit FGF pathway.
Magic-F1 may interfere with the balance between stem cell
self-renewal and cell diﬀerentiation in developing muscles,
mainly operated by Pax3 and Pax7 (paired box gene 7) [28].
It is unlikely that it is directly involved in stem-cell renewal;
however, competing with HGF, the natural Met ligand could
be move the balance towards muscle diﬀerentiation.
Further studies are necessary to elucidate Magic-F1
specific role in cell specification and diﬀerentiation during
embryogenesis.
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